In a report released today, Michael Matson from Needham reiterated a Buy rating on Atricure (NASDAQ: ATRC), with a price target of $39. The company’s shares closed yesterday at $32.54.
Matson observed:
“On 10/3/18, ATRC preannounced 3Q18 revenue that was above consensus as 3Q18 revenue accelerated to 18.6% from 13.5% in 2Q18. We note that ATRC had an easy comp due to last year’s hurricanes; management estimates revenue growth was ~16% adjusting for this. Management raised its 2018 revenue guidance but lowered its adjusted EBITDA guidance. Excluding certain items, gross margin declined Y/Y by 40 bps while operating margin improved Y/Y by 360 bps. We believe recent society guidelines, new products, and surgeon training activities should drive strong growth in the near-term and that CONVERGE could be a significant longer- term tailwind and we reiterate our Buy rating.”
According to TipRanks.com, Matson is a 5-star analyst with an average return of 11.6% and a 62.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
Atricure has an analyst consensus of Strong Buy, with a price target consensus of $38.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.49 and a one-year low of $14.88. Currently, Atricure has an average volume of 245.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AtriCure, Inc. engages provision of treatment of atrial fibrillation and left atrial appendage. It operates through the following geographical segments: United States, Europe, Asia, and Other International.
